An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus (original) (raw)

References

  1. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 244, 359–362 (1989)
    Article ADS CAS PubMed Google Scholar
  2. Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362–364 (1989)
    Article ADS CAS PubMed Google Scholar
  3. Di Bisceglie, A. M. Hepatitis C. Lancet 351, 351–355 (1998)
    Article CAS PubMed Google Scholar
  4. Chander, G. et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 36, S135 (2002)
    ADS PubMed Google Scholar
  5. Tan, S.-L., Pause, A., Shi, Y. & Sonenberg, N. Hepatitis C therapeutics: current status and emerging strategies. Nature Rev. Drug Discov. 1, 867–881 (2002)
    Article CAS Google Scholar
  6. Di Bisceglie, A. M., McHutchison, J. & Rice, C. M. New therapeutic strategies for hepatitis C. Hepatology 35, 224–231 (2002)
    Article PubMed Google Scholar
  7. Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242, 55–84 (2000)
    CAS PubMed Google Scholar
  8. Kolykhalov, A. A., Mihalik, K., Feinstone, S. M. & Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74, 2046–2051 (2000)
    Article CAS PubMed PubMed Central Google Scholar
  9. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 103–107 (1999)
    Article Google Scholar
  10. Mercer, D. F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nature Med. 7, 927–933 (2001)
    Article CAS PubMed Google Scholar
  11. Schechter, I. & Berger, A. Protease subsite nomenclature. Biochem. Biophys. Res. Commun. 27, 157–162 (1967)
    Article CAS PubMed Google Scholar
  12. Llinàs-Brunet, M. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 1713–1718 (1998)
    Article PubMed Google Scholar
  13. Steinkühler, C. et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37, 8899–8905 (1998)
    Article PubMed Google Scholar
  14. Llinàs-Brunet, M. et al. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 2719–2724 (1998)
    Article PubMed Google Scholar
  15. Llinàs-Brunet, M. et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10, 2267–2270 (2000)
    Article PubMed Google Scholar
  16. Poupart, M.-A. et al. Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease. J. Org. Chem. 66, 4743–4751 (2001)
    Article CAS PubMed Google Scholar
  17. Goudreau, N. et al. NMR structural characterization of peptide inhibitors bound to the HCV NS3 protease: design of a new P2 substituent. J. Med. Chem. (submitted)
  18. Pause, A. et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 278, 20374–20380 (2003)
    Article CAS PubMed Google Scholar
  19. LaPlante, S. R. et al. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J. Biol. Chem. 274, 18618–18624 (1999)
    Article CAS PubMed Google Scholar
  20. LaPlante, S. R. et al. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain. Bioorg. Med. Chem. Lett. 10, 2271–2274 (2000)
    Article CAS PubMed Google Scholar
  21. Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor tripeptides. US patent 6,323,180 B1 (2001).
  22. Tsantrizos, Y. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Edn Engl. 42, 1356–1360 (2003)
    Article CAS Google Scholar
  23. Narjes, H., Yong, C. L., Stahle, H. & Steinmann, G. Tolerability and pharmacokinetics of BILN 2061: a novel serine protease HCV inhibitor after oral single doses of 5 mg to 2,400 mg in healthy male subjects. Hepatology 36(4), Abst. 800 (2002)
    Google Scholar
  24. Hinrichsen, H. et al. First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 36, 297A, Abst. 866 (2002)
    Google Scholar
  25. Benhamou, Y. et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 36, 304A, Abst. 563 (2002)
    Google Scholar
  26. Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103–107 (1998)
    Article ADS CAS PubMed Google Scholar
  27. Neumann, A. U. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182, 28–35 (2000)
    Article CAS PubMed Google Scholar
  28. Zeuzem, S. et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. Gastroenterology 120, 1438–1447 (2001)
    Article CAS PubMed Google Scholar
  29. Foy, E. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145–1148 (2003)
    Article ADS CAS PubMed Google Scholar
  30. Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the Hepatitis C virus. US patent 6,608,027 B1 (2003).

Download references

Acknowledgements

We wish to thank F. Dô, J. Duan, M. Garneau, N. Lapeyre-Paquette, S. Lefebvre, F. Liard, M. Marquis, R. Maurice, G. McKercher, A. Pause, C. Pellerin, L. Pilote, C. Plouffe and M. Rhéaume from the Biological Sciences Department, and N. Aubry, J. Bordeleau, C. Boucher, Y. Bousquet, C. Brochu, C. Chabot, R. Déziel, J.-S. Duceppe, G. Fazal, J.-M. Ferland, E. Ghiro, J. Gillard, V. Gorys, S. Goulet, C. Grand-Maître, B. Haché, T. Halmos, P. Lavallée, M. Little, E. Malenfant, R. Plante, M. Poirier, S. Valois and D. Wernic from the Chemistry Department. We also thank B. Willems and the Centre de Recherche Clinique André Viallet, Hôpital St-Luc, CHUM. We acknowledge the BILN 2061 development team and members of the departments of Drug Metabolism and Pharmacokinetics, Pharmacology, Pharmaceutics, Analytical Sciences, Process Chemistry, Toxicology, Drug Regulatory Affairs and Medical at Boehringer Ingelheim Pharmaceuticals, Inc., Connecticut, USA; J. Croenlein, G. Nehmiz and the clinical research teams at Boehringer Ingelheim Pharma KG, Biberach, Germany; and Academisch Medisch Centrum, The Netherlands. We thank the volunteers and patients who participated in the clinical trials of BILN 2061. R.E.S. was clinical investigator and received honorarium from Boehringer Ingelheim. All other authors are or were employees of Boehringer Ingelheim.

Author information

Author notes

  1. Dale R. Cameron
    Present address: Micrologix Biotech Inc., BC Research Complex, 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2, Canada

Authors and Affiliations

  1. Departments of Biological Sciences Boehringer Ingelheim (Canada) Ltd, Laval, Québec, H7S 2G5, Canada
    Daniel Lamarre, Gordon Bolger, Pierre Bonneau, Mireille Cartier, Michael G. Cordingley, George Kukolj, Lisette Lagacé & Diane Thibeault
  2. Chemistry, Research and Development, Boehringer Ingelheim (Canada) Ltd, Laval, Québec, H7S 2G5, Canada
    Paul C. Anderson, Murray Bailey, Pierre Beaulieu, Michael Bös, Dale R. Cameron, Anne-Marie Faucher, Nathalie Goudreau, Stephen H. Kawai, Steven R. LaPlante, Marc-André Poupart, Jean Rancourt, Bruno Simoneau, Youla S. Tsantrizos & Montse Llinàs-Brunet
  3. Clinical Research, Boehringer Ingelheim Pharma KG, Biberach, 88397, Germany
    Hans Narjes & Gerhard Steinmann
  4. Academisch Medisch Center, Amsterdam, 1105 AZ, The Netherlands
    Roel E. Sentjens
  5. Research and Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, 06877-0368, USA
    Roger St George, Steven M. Weldon & Chan-Loi Yong

Authors

  1. Daniel Lamarre
    You can also search for this author inPubMed Google Scholar
  2. Paul C. Anderson
    You can also search for this author inPubMed Google Scholar
  3. Murray Bailey
    You can also search for this author inPubMed Google Scholar
  4. Pierre Beaulieu
    You can also search for this author inPubMed Google Scholar
  5. Gordon Bolger
    You can also search for this author inPubMed Google Scholar
  6. Pierre Bonneau
    You can also search for this author inPubMed Google Scholar
  7. Michael Bös
    You can also search for this author inPubMed Google Scholar
  8. Dale R. Cameron
    You can also search for this author inPubMed Google Scholar
  9. Mireille Cartier
    You can also search for this author inPubMed Google Scholar
  10. Michael G. Cordingley
    You can also search for this author inPubMed Google Scholar
  11. Anne-Marie Faucher
    You can also search for this author inPubMed Google Scholar
  12. Nathalie Goudreau
    You can also search for this author inPubMed Google Scholar
  13. Stephen H. Kawai
    You can also search for this author inPubMed Google Scholar
  14. George Kukolj
    You can also search for this author inPubMed Google Scholar
  15. Lisette Lagacé
    You can also search for this author inPubMed Google Scholar
  16. Steven R. LaPlante
    You can also search for this author inPubMed Google Scholar
  17. Hans Narjes
    You can also search for this author inPubMed Google Scholar
  18. Marc-André Poupart
    You can also search for this author inPubMed Google Scholar
  19. Jean Rancourt
    You can also search for this author inPubMed Google Scholar
  20. Roel E. Sentjens
    You can also search for this author inPubMed Google Scholar
  21. Roger St George
    You can also search for this author inPubMed Google Scholar
  22. Bruno Simoneau
    You can also search for this author inPubMed Google Scholar
  23. Gerhard Steinmann
    You can also search for this author inPubMed Google Scholar
  24. Diane Thibeault
    You can also search for this author inPubMed Google Scholar
  25. Youla S. Tsantrizos
    You can also search for this author inPubMed Google Scholar
  26. Steven M. Weldon
    You can also search for this author inPubMed Google Scholar
  27. Chan-Loi Yong
    You can also search for this author inPubMed Google Scholar
  28. Montse Llinàs-Brunet
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toDaniel Lamarre.

Ethics declarations

Competing interests

The authors have amended their Competing interests statement: it previously read 'The authors declare that they have no competing financial interests.' it should read ‘The authors declare competing financial interests: R.E.S. was the clinical investigator and received an honorarium from Boehringer Ingelheim. All the other authors are or were employees of Boehringer Ingelheim.’ A Corrigendum will soon be published.

Supplementary information

Rights and permissions

About this article

Cite this article

Lamarre, D., Anderson, P., Bailey, M. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.Nature 426, 186–189 (2003). https://doi.org/10.1038/nature02099

Download citation